ZYLOX-TONBRDG.MED.TECH.H1 Capital Reinvestment Ratio
ZYLOX-TONBRDG.MED.TECH.H1 capital reinvestment ratio. ZYLOX-TONBRDG.MED.TECH.H1 (818) has a Capital Reinvestment Ratio of 1.10x as of December 2024, meaning it reinvests 1% of its operating cash flow (€174.08 Million) in capital expenditures (€191.34 Million). Check how aggressively does ZYLOX-TONBRDG.MED.TECH.H1 reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Capital Reinvestment Ratio of ZYLOX-TONBRDG.MED.TECH.H1 (2023–2024)
Capital reinvestment ratio of ZYLOX-TONBRDG.MED.TECH.H1 from 2023 to 2024. This chart tracks ZYLOX-TONBRDG.MED.TECH.H1's Capital Reinvestment Ratio across 2 annual periods. Also explore how fast is ZYLOX-TONBRDG.MED.TECH.H1 growing its equity to track the company's year-over-year net asset growth rate.
ZYLOX-TONBRDG.MED.TECH.H1 Capital Reinvestment Ratio by Year (2023–2024)
ZYLOX-TONBRDG.MED.TECH.H1 capital reinvestment ratio by year from 2023 to 2024. For the full cash flow conversion analysis, see 818 cash generation efficiency.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 1.10x | €174.08 Million | €191.34 Million | ▼ -43.3% |
| 2023 | 1.94x | €98.44 Million | €190.92 Million | — |